Purpose of the Review
Glucocorticoid (GC) toxicity is a major concern in the management of giant cell arteritis (GCA). Tocilizumab (TCZ) has been introduced as a GC-sparing agent in GCA. This review critically analyses the extent of the GC-sparing capacity of TCZ and explores its impact on molecular and imaging findings.
Recent Findings
Two randomized controlled trials investigated the GC-sparing potential of TCZ in the treatment of GCA. Four Proof-of-concept studies have investigated the extent to which GC exposure can be further minimized. Recent evidence highlights the chronicity of GCA, emphasizing the need for low-toxicity treatment strategies and advocating for long-term follow-up.
Summary
Reducing GC toxicity is one of the most important trends in the management of GCA. New treatment strategies include TCZ and reducing GC exposure and toxicity in patients diagnosed with GCA.
